INTRODUCTION
Colorectal cancer (CRC) is the 4 th leading cancer diagnosis and 2 nd cause of cancer death in the United States, with an estimated 140,000 diagnoses and 50,000 deaths annually.
(1) Despite 36% of CRC patients being age 75 or older at diagnosis, guidance on how to approach the treatment of this population is limited.
Among those selected to receive chemotherapy, survival outcomes are similar to younger patients in most, (2) (3) (4) but not all studies. (5) Yet, only one-third of older adults receive indicated chemotherapy. (6) There is a paucity of research concerning which factors should determine patient selection for treatment and the resulting survival outcomes. Most of this limited research focuses on age alone as a predictor of treatment and survival outcomes.
Advancing age has long been recognized as a potent risk factor for the development of cancer, further underscored by the fact that nearly 60% of CRC is diagnosed in those age ≥65. Several investigators have postulated mechanisms by which aging impacts CRC carcinogenesis, including accumulation of somatic mutations over time and epigenetic silencing. (7) Baseline rates of detectable somatic mosaicism in the general population are low, but generally higher in older adults (~2% in people with age ≥75) than in younger adults (< 0.5% in people with age <50). (7, 8) However, the degree to which CRC carcinogenesis differs by age at diagnosis, as driven by somatic mutations and epigenetic changes, is not well known. We hypothesized that adverse prognostic associations of key molecular factors would be disproportionately higher in older adults than younger adults at diagnosis of CRC.
To test this hypothesis, we examined the prognostic associations of CpG island methylator phenotype (CIMP), microsatellite instability (MSI), KRAS, BRAF, and PIK3CA mutations, and CTNNB1 (ß-catenin) nuclear expression status according to age group (at CRC diagnosis) among 1280 cases of CRC within two large
prospective longitudinal cohorts. We tested the statistical interaction of age at CRC diagnosis with each molecular factor on CRC-specific survival and overall survival. The combined prospective cohorts used for analysis provide the unique advantage of a large age distribution of incident, previously untreated CRC cases with well-annotated tumor molecular data to address the hypothesis.
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MATERIALS AND METHODS

Study Population
Initiated in 1976, the Nurses' Health Study (NHS)(9) is a prospective U.S. nationwide cohort of 121,700 female registered nurses age 30 to 55 years at the time of enrollment, who responded to a mailed questionnaire regarding cancer and cardiovascular risk. The Health Professionals Follow-up Study (HPFS) subsequently enrolled 51,529 male health professionals, age 40 to 75 years beginning in 1986. Both cohorts continue to complete biennial follow-up questionnaires updating information on medical history and potential risk factors.
The studies were approved by the Human Subjects Committees at Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital (both Boston, MA). All participants signed informed consent permitting questionnaire, blood and tumor data to be used in research studies.
The study population consists of NHS and HPFS subjects with pathologically confirmed colon or rectal carcinoma diagnosed up to June 1, 2010 for NHS and January 1, 2010 for HPFS with available CRC tumor specimen for analysis ( Figure 1 ). Subjects with other cancer occurring within 3 years before colorectal cancer diagnosis (except non-melanoma skin cancer) were excluded from the analysis (n=33). The final cohort includes 1280 subjects including 690 from NHS and 590 from HPFS.
Identification of Colorectal Cancer
For respondents reporting a diagnosis of CRC within the prior 2 years, we requested permission to review all hospital and pathology records pertaining to CRC. Once obtained, study physicians blinded to patient outcomes extracted information on American Joint Committee on Cancer (AJCC) stage, histology, tumor location and date of diagnosis. Cause and date of death were obtained from the National Death Index (NDI) for non-respondents.(10) Nearly 96% of all incident CRC cases were identified by either of these two methods.(11) For deceased participants with known or suspected cancer for which we have not been able to obtain medical records, we contacted the state tumor registry to confirm and classify the cancer. CRC treatment data are not available in these databases.
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Analysis of Tumor Molecular Factors
The term molecular factors is used in this study to denote the accumulated somatic mutations associated with promotion of CRC. Archival CRC tumor specimens were collected from the hospitals at which subjects underwent resection or biopsy of CRC. All genomic DNA extraction from paraffin-embedded tissue and whole genome amplification by polymerase chain reaction (PCR) were performed as previously described.(9) All CRC tumor block specimens and hematoxylin and eosin (H&E)-stained tissue sections were reviewed by a pathologist (S.O.) with established quality control measures consistent with the strategy used in prior NHS/HPFS analyses.(9) We use HUGO (Human Genome Organisation)-approved official symbols for genes and gene products -including BRAF, CTNNB1 [catenin (cadherin-associated protein), beta 1, 88kDa; socalled β-catenin], KRAS, and PIK3CA. (12) Analysis of PIK3CA, KRAS, BRAF and CIMP PCR and pyrosequencing of PIK3CA (exons 9 and 20), (11, 13 ) KRAS (codons 12, 13, 61 and 146), (14, 15) and BRAF (codon 600) were performed as previously described. 
Analysis of MSI
MSI status was quantified using a 10-marker panel using D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and D18S487.(21) MSI-high was defined as presence of instability in ≥30% of the markers, microsatellite instability low (MSI-low as 1-29% unstable markers, and microsatellite stability (MSS) as no unstable marker. Given no difference in prognosis between MSI-low and MSS tumors in prior analysis,(9) they were combined in the present study.
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Analysis of CTNNB1 (β-catenin)
Immunohistochemistry for CTNNB1 nuclear expression was performed as previously described, and interpreted as negative (weak or no expression) or positive (moderate or strong expression) by a pathologist (T.M.). (22) A subset of cases (n=292) were independently interpreted by a second pathologist (S.O.); agreement between the two pathologists was 0.90 for CTNNB1 nuclear expression (κ=0.80; p<0.0001), indicating good to substantial agreement.
Definition of Age
The age at diagnosis was classified into three age groups (<60, 60-74 and ≥75). Older adults are defined as those age ≥75 years at diagnosis. Sensitivity analyses were conducted to examine other definitions of age to allow comparisons consistent with prior studies in the epigenetic,(9) CRC and geriatric oncology (5, 23) literature.
Outcome Measurement
Patients are observed until death and censored at last questionnaire prior to data analysis as of January 1, 2011. The two primary outcomes are CRC-specific survival and overall survival. For NHS/HPFS, follow-up began from date of CRC diagnosis. CRC-specific survival is defined as the time from CRC diagnosis to CRCspecific death; deaths from other causes are censored at the time of death. Overall survival is defined as the time from CRC diagnosis to death due to any cause. Date of death was obtained by report from family, postal authority or confirmation via the NDI.(10) Cause of death was assigned by study physicians blinded to Prognostic molecular factors in CRC by age 9
Statistical Analysis
Cox proportional hazards models were used to calculate hazard ratios (HRs) of death or death resulting from CRC according to molecular factors, adjusted using the stepwise variable selection method including BMI (<30, 30+, missing), prediagnosis activity (<18, 18+, missing), tumor location, tumor differentiation, and other markers (MSI, CIMP, KRAS, BRAF, CTNNB1 and PIK3CA). Gender, regular aspirin use and comorbidity (DM, MI/CHF, CVA) were forced in the model. Regular aspirin use is defined as at least 2 tablets/week in NHS and at least 2 times/week in HPFS. Disease stage was used as a stratifying variable. The analysis results are from
Cox regression models where all patient data is censored at 5 years or 10 years for the respective CRCspecific and overall survival. We tested interaction impact of age on the association between each molecular factor and survival by including the cross-product of age as a continuous variable and each molecular factor in the model. We evaluated the distribution of molecular tumor factors using the Χ 2 test (categorical variables) and analysis of variance (ANOVA, continuous variables) across patient and disease factors. We considered multiple hypothesis testing adjusting the p for significance level to p=0.01 given 5 molecular factors evaluated.
All analyses used SAS software, version 9.3 (SAS Institute, Inc, Cary, NC). Smoothing splines of log hazard were used to visualize the relationship between CRC-specific and overall survival at 5 years by molecular factor status.
RESULTS
Patient characteristics
The incident CRC cases with tumor sample availability in the combined NHS/HPFS cohort included 1280 patients (n=224 age <60, 756 age 60-74 and 300 age ≥75). We assessed patient and disease characteristics according to age at diagnosis (Table 1) . Older patients were more likely to be male (65% vs. 30% age <60, 43% age 60-74), have a lower body mass index (93% BMI <30 vs. 86% age <60, 83% age 60-74), present with lower rate of stage IV disease at diagnosis (8% vs. 16% age <60, 14% age 60-74) and have tumors in the proximal colon (52% vs. 36% age <60, 49% age 60-74) (all p<0.001). Of those with reporting presence of comorbid medical conditions, older adults had the highest rate of prior cerebrovascular accident (56% vs. 1%
Research. Prognostic molecular factors in CRC by age 10 age <60, 43% age 60-74) but second highest rate of DM (35% vs. 7% age <60, 57% age 60-74) and MI or CHF (45% vs. 2% age <60, 54% age 60-74) ( Table 1) . We adjusted all analyses for the presence of cerebrovascular accident, diabetes mellitus and myocardial infarction/congestive heart failure. There were no appreciable differences in race, year of diagnosis, tumor differentiation, number of lymph nodes examined, and number of lymph nodes positive.
Prevalence of molecular factors by age
We examined the distribution of potentially prognostic and/or predictive molecular changes in CRC tumor samples by age ( Table 2 ). Fifteen percent of the overall cohort had MSI-high tumors; there was a statistically significant difference in the rate of MSI-high across age groups (8% age < 60, 17% age 60-74, 16% age ≥75; p=0.006) ( Table 2) . Similarly, 16% of the overall cohort has CIMP-high tumors and the distribution of CIMPhigh was statistically significantly increased in older adults (5% age < 60; 18% age 60-74, and 18% age ≥75; p<0.0001). There were no differences in rates of KRAS mutation (p=0.53), BRAF mutation (p=0.14), PIK3CA mutation (p=0.50), and CTNNB1 nuclear expression positive (p=0.69) among the three age groups.
Prognostic utility of molecular factors by age
At 5 years following diagnosis, 297 (23%) patients died of CRC (22% <60; 23% age 60-74, 24% ≥75; p=0.90) and 372 (29%) patients died of CRC or other causes (23% <60; 28% age 60-74, 35% ≥75; p=0.008). Similar differences in CRC-specific and overall survival were noted at 10 years (p=0.98 and <0.001, respectively).
Despite the observed similar rates of events at each time point, older age was associated with inferior CRCspecific and overall survival at 5 (CRC-specific survival p=0.003, overall survival p<0.0001) and 10 years (CRC-specific survival p=0.0002, overall survival p<0.0001), adjusting for gender, regular aspirin use, comorbid medical conditions (DM, MI/CHF, CVA), BMI, prediagnosis physical activity, tumor location, and tumor differentiation, stratifying by disease stage (Table 3) , possibly reflecting difference in treatment receipt and tolerance.
The associations of molecular factors on CRC-specific and overall survival by age are depicted in Table   4 and Prognostic molecular factors in CRC by age 11 survival at 10 years among the three age groups by each molecular factor. For the overall cohort, MSI-high was associated with improved CRC-specific and overall survival (data not shown) but there was no statistically significant interaction by age (p=0.17 for CRC-specific survival and p=0.94 for overall survival). In contrast, CIMP-high, KRAS mutation and PIK3CA was not associated with CRC-specific and overall survival (data not shown) and not associated with a statistically significant interaction by age (CRC-specific survival: p=0.92, 0.89, and 0.24, respectively; overall survival: p=0.53, 0.57, and 0.09, respectively). In contrast, BRAF mutation was associated with inferior CSS and OS within age group 60-74 years (CRC-specific survival: p=0.002; overall survival: p=0.02) but not in the other age groups [(age <60 -CRC-specific survival: p=0.65; overall survival: p=0.73), (age ≥75 -CRC-specific survival: p=0.83; overall survival: p=0.94)]. There was no statistically significant interaction of BRAF and CRC-specific and overall survival by age (p=0.25, 0.71 respectively). Although statistical power was limited in subgroup analyses, among those patients whose tumors are both MSI-high and CIMP-high, BRAF mutation might be prognostic of inferior survival [HR 1.48 (95% CI 0.97 to 2.24) for CRC-specific survival at 10 years; HR 1.28 (95% CI 0.91 to 1.80) for overall survival at 10 years]. However, there was no statistically significant interaction of age and BRAF mutation, among MSIhigh/CIMP-high (p-within age strata = 0.07 for CRC-specific survival, p-within age strata = 0.15 for overall survival).
Positive CTNNB1 nuclear expression was associated with a trend toward inferior survival at 10 years and the adverse prognostic impact of positive CTNNB1 nuclear expression was significantly greater among older patients (p-interaction=0.03 for CRC-specific survival and 0.007 for overall survival). As depicted in Supplemental Figure 1 , splines show the association of CTNNB1 nuclear expression status with CRC-specific and overall survival. The inflections within the splines for hazard ratios greater than 1 were observed at older age, as suggested in the trend toward inferior survival noted in Cox proportional hazards analyses. This association was not consistently modified by tumor location or presence of comorbid medical conditions. Older age was associated with nuclear CTNNB1 expression in the proximal colon (8% age <60, 15% age 60-75, 22% age ≥75; p=0.03). However, CTTNB1 expression in the distal colon or rectum was not appreciably different by age (data not shown; p=0.66 and p=0.30, respectively). Further, there was not a statistically significant difference in positive nuclear CTNNB1 expression by presence of diabetes mellitus (3% age <75 vs.
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accident (2% age <75 vs. 7% age ≥75; p=0.07).
The observed association of examined molecular factors on CRC-specific and overall survival was not altered when alternative modeling of age is used (data not shown). For example, we examined age as a continuous variable as well as divided into two categories (age <70, ≥70) consistent with prior oncologic and geriatric literature, (2, 5, (29) (30) (31) (32) noting no change in associations of CTNNB1 on CRC-specific and overall survival.
DISCUSSION
In this prospective cohort of men and women diagnosed with colorectal cancer (CRC), we hypothesized that adverse prognostic associations of key molecular factors would be disproportionately higher in older adults than younger adults at diagnosis of CRC. We noted a higher prevalence of MSI-high and CIMP-high as well as a similar prevalence of KRAS mutation, BRAF mutation, positive CTNNB1 (β-catenin) nuclear expression and PIK3CA mutation in older adults compared to younger counterparts. Regardless of age, MSI-high was associated with better prognosis and BRAF mutation was associated with worse survival (consistent with earlier analysis(9, 33)), whereas neither CIMP, KRAS, nor PIK3CA status was associated with prognosis.
Positive CTNNB1 nuclear expression in CRC tumors was associated with a trend toward worse prognosis among older adults with a statistically significant interaction by age, making CTNNB1 an interesting molecular factor of interest for older adults diagnosed with CRC. The combined NHS/HPFS database provided the unique advantage of integrative molecular pathological epidemiology(46) data within a large age distribution of incident previously untreated CRC cases.
Nonetheless, there are limitations to this analysis. We lack available treatment data for the cohort. While the yield and quality of CRC tumor specimens in NHS/HPFS were high, there were some incident CRC cases for which tumor specimens were not available. However, there were no substantial differences in patient or tumor characteristics between incident CRC patients with and without available tumor specimens. (9) In addition, residual confounding might be an issue in any observational study; however, one of the advantages of the Prognostic molecular factors in CRC by age 14 NHS/HPFS cohorts is availability of data on potential confounders including comorbidities and detailed clinical and tumor characteristics. Lastly, the majority of the younger cohort age <60 were diagnosed with CRC before 2002. This is a consequence of the age at which patients were enrolled in the NHS and HPFS cohorts, potentially negatively impacting the overall cancer specific survival within this age group.
In conclusion, our findings suggest an age-specific pattern of molecular factors associated with CRCspecific and overall survival among older adults diagnosed with CRC. Specifically, we observed trend toward an inferior survival among older adults by tumor CTNNB1 nuclear expression status compared to younger counterparts. Given the call to integrate molecular, histopathologic and physiologic factors in the study of aging and cancer,(7) subsequent planned investigation includes determination of the molecular characterization of CRC by age and evaluation of interaction with chemotherapy treatment among older adults. Determination of the mechanisms underlying observed differences in survival and treatment response for older adults diagnosed with CRC may ultimately be translated from the laboratory to patient care to inform subsequent development of prevention strategies, targeted therapies and treatment selection for this population. 
